Table 3 Linear regression analyses
From: Clinical relevance of circulating angiogenic cells in patients with ischemic stroke
Beta | Std. Error | p value | OR | 2.5% | 97.5% | |
|---|---|---|---|---|---|---|
a Multiple linear regression analysis for CACs | ||||||
(Intercept) | 6.59239 | 0.97212 | 1.59e−08 | 729.5 | 10.5 | 50,438 |
Thrombolysis | 0.86720 | 0.15830 | 1.55e−06 | 2.38 | 1.194 | 4.745 |
Hypertension | 0.64078 | 0.21456 | 0.00443 | 1.898 | 0.745 | 4.834 |
LOECs | − 0.65849 | 0.29737 | 0.03158 | 0.518 | 0.142 | 1.891 |
Risks | 0.20930 | 0.08672 | 0.01967 | 1.233 | 0.845 | 1.799 |
VEGF | − 0.05366 | 0.01025 | 3.58e−06 | 0.948 | 0.906 | 0.991 |
Beta | Std. Error | Pr( >|t|) | OR | 2.5% | 97.5% | |
|---|---|---|---|---|---|---|
b Multiple regression analysis for CFU-ECs | ||||||
(Intercept) | − 0.87925 | 1.23767 | 0.48527 | 0.415 | 0.032 | 5.445 |
Hemoglobine | 0.19561 | 0.08806 | 0.03746 | 1.216 | 1.013 | 1.460 |
RR | − 1.24604 | 0.42851 | 0.00841 | 0.288 | 0.118 | 0.701 |